38.37
Caredx Inc stock is traded at $38.37, with a volume of 1.18M.
It is down -3.42% in the last 24 hours and up +46.56% over the past month.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
See More
Previous Close:
$39.73
Open:
$39.3
24h Volume:
1.18M
Relative Volume:
1.29
Market Cap:
$1.98B
Revenue:
$412.82M
Net Income/Loss:
$-8.19M
P/E Ratio:
-248.99
EPS:
-0.1541
Net Cash Flow:
$64.17M
1W Performance:
+33.41%
1M Performance:
+46.56%
6M Performance:
+89.95%
1Y Performance:
+222.03%
Caredx Inc Stock (CDNA) Company Profile
Name
Caredx Inc
Sector
Industry
Phone
415-287-2300
Address
8000 MARINA BLVD, BRISBANE, CA
Compare CDNA vs TMO, DHR, IDXX, NTRA, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
CDNA
Caredx Inc
|
38.37 | 2.05B | 412.82M | -8.19M | 64.17M | -0.1541 |
|
TMO
Thermo Fisher Scientific Inc
|
526.23 | 197.88B | 45.20B | 6.87B | 6.75B | 18.19 |
|
DHR
Danaher Corp
|
201.11 | 144.26B | 24.78B | 3.68B | 5.29B | 5.1743 |
|
IDXX
Idexx Laboratories Inc
|
563.81 | 44.76B | 4.45B | 1.10B | 1.06B | 13.59 |
|
NTRA
Natera Inc
|
262.63 | 38.87B | 2.50B | -226.32M | 71.51M | -1.6412 |
|
A
Agilent Technologies Inc
|
130.26 | 37.13B | 7.23B | 1.41B | 1.09B | 4.979 |
Caredx Inc Stock (CDNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-06-26 | Downgrade | Craig Hallum | Buy → Hold |
| Aug-26-25 | Initiated | William Blair | Mkt Perform |
| Jan-15-25 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Aug-28-24 | Initiated | Wells Fargo | Underweight |
| Aug-19-24 | Upgrade | BTIG Research | Neutral → Buy |
| May-13-24 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-01-24 | Upgrade | Craig Hallum | Hold → Buy |
| Nov-09-23 | Upgrade | Stephens | Equal-Weight → Overweight |
| Aug-15-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-11-23 | Downgrade | BTIG Research | Buy → Neutral |
| Mar-07-23 | Downgrade | Stephens | Overweight → Equal-Weight |
| Mar-03-23 | Downgrade | Craig Hallum | Buy → Hold |
| Mar-03-23 | Downgrade | Raymond James | Strong Buy → Mkt Perform |
| Apr-25-22 | Initiated | Stephens | Overweight |
| Jul-20-21 | Resumed | BTIG Research | Buy |
| Jun-03-21 | Initiated | Goldman | Buy |
| Feb-26-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-30-20 | Reiterated | H.C. Wainwright | Buy |
| Oct-08-20 | Reiterated | H.C. Wainwright | Buy |
| Oct-02-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-05-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-26-20 | Initiated | BTIG Research | Buy |
| Jun-19-20 | Reiterated | H.C. Wainwright | Buy |
| Oct-01-19 | Resumed | Craig Hallum | Buy |
| May-09-19 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Feb-15-19 | Initiated | Jefferies | Buy |
| Oct-23-18 | Resumed | Raymond James | Strong Buy |
| Sep-18-18 | Reiterated | H.C. Wainwright | Neutral |
| Nov-27-17 | Initiated | H.C. Wainwright | Buy |
| Jun-14-16 | Reiterated | Mizuho | Buy |
| Sep-29-15 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Sep-25-15 | Initiated | Craig Hallum | Buy |
| Mar-18-15 | Reiterated | Mizuho | Buy |
View All
Caredx Inc Stock (CDNA) Latest News
CareDx Inc (CDNA) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
CareDx (CDNA) Q3 2024 earnings summary - Quartr
CareDx (CDNA) Proxy filing Summary - Quartr
CareDx’s Growth Prospects With Naveris Keep Me Bullish (NASDAQ:CDNA) - Seeking Alpha
CareDx (CDNA) Is Up 39.4% After Final Medicare Coverage Clarifies Transplant Test Reimbursement Limits - simplywall.st
CareDx (CDNA) Is Up 39.4% After Medicare Clarifies Transplant Test Coverage LimitsWhat's Changed - Yahoo Finance
CareDx (CDNA) Secures Medicare Reimbursement Clarity, Is The Upside Already Priced In? - Yahoo Finance
CareDx rallies after Medicare finalizes transplant testing coverage policy - MSN
Form 4 Caredx Inc For: 17 July By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Neutral stock rating on CareDx - Investing.com UK
CareDx director Hannah Valantine disposes of common shares worth $1.04 million - Bitget
H.C. Wainwright reiterates Neutral stock rating on CareDx By Investing.com - Investing.com Nigeria
CareDx CEO John Hanna sells $4.46m in company stock - Investing.com
CareDx CEO John Hanna sells $4.46m in company stock By Investing.com - Investing.com UK
[Form 4] CareDx, Inc. Insider Trading Activity - Stock Titan
CareDx (CDNA) director sells 28,779 shares and exercises options - Stock Titan
A Quick Look at Today's Ratings for CareDx(CDNA.US), With a Forecast Between $35 to $45 - Moomoo
CareDx (CDNA) Moves 35.6% Higher: Will This Strength Last? - Yahoo Finance
BTIG raises CareDx stock price target to $45 on coverage decision - Investing.com UK
Form 144 CAREDX For: 16 July By Investing.com - Investing.com Nigeria
CareDx says final Medicare LCD maintains coverage for transplant rejection surveillance tests - Bitget
CareDx sets webcast to discuss second-quarter 2026 results after market close - Bitget
BTIG raises CareDx stock price target to $45 on coverage decision By Investing.com - Investing.com South Africa
Price to earnings forward of CareDx, Inc. – GETTEX:1K9 - TradingView
CareDx Inc. (CDNA) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Form 144 | CareDx(CDNA.US) Director Proposes to Sell 3.51 Million in Common Stocks - Moomoo
CareDx (CDNA) Jumps As Naveris Deal Redraws Growth Map - timothysykes.com
CDNA (NASDAQ: CDNA) holder John Hanna files notice to sell 118,000 shares - Stock Titan
Planned 28,779-share CDNA (NASDAQ: CDNA) sale follows earlier 10b5-1 trade - Stock Titan
Caredx Inc stock hits 52-week high at 36.4 USD By Investing.com - Investing.com South Africa
CAREDX INC : BTIG RAISES TARGET PRICE TO $45 FROM $28 - Bitget
CareDx shares jump as Medicare finalizes transplant testing coverage policy (CDNA) - MSN
CDNA Maintained by BTIG -- Price Target Raised to $45 - GuruFocus
Why Is CareDx Stock Skyrocketing Thursday? - Benzinga
Caredx Inc stock hits 52-week high at 36.4 USD - Investing.com
CareDx to report Q2 2026 financial results on July 30 - scanx.trade
CareDx Announces Finalization of Solid Organ Transplant Molecular Testing Local Coverage Determination - Finviz
CareDx (CDNA) Secures Medicare Coverage for Molecular Testing - GuruFocus
CareDx stock surges 20% on Medicare coverage policy By Investing.com - Investing.com India
CareDx stock surges 20% on Medicare coverage policy - Investing.com
Press Release: CareDx to Report Second Quarter 2026 Financial Results on July 30, 2026 - Moomoo
CareDx to Report Second Quarter 2026 Financial Results on July 30, 2026 - Business Wire
How Caredx Inc. (CDNA) Affects Rotational Strategy Timing - Stock Traders Daily
CareDx (CDNA) Following Reimbursement Progress Is The Stock Starting To Look Fully Valued - Sahm
Price to earnings forward of CareDx, Inc. – LSX:A118WG - TradingView
Frontier tech research, news & data - MLQ.ai
CareDx to Participate in Upcoming Investor Conferences - AOL.com
Form 4 Caredx Inc For: 7 July By Investing.com - Investing.com Nigeria
CareDx (CDNA) director receives 1,746-share quarterly stock grant as compensation - Stock Titan
CareDx (CDNA) exits lab products and acquires Naveris to expand $12B market - Stock Titan
CareDx Completes Naveris Acquisition and Expands Oncology Reach - Yahoo Finance
Caredx Inc Stock (CDNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):